A rise in ageing population has been found to be the major causative factor for development of Parkinson’s disease. Parkinson’s disease is the second-most common chronic and progressive neurodegenerative disorder featuring the cardinal symptoms of postural instability, bradykinesia, akinesia and tremors due to loss of dopamine producing neurons in substantia nigra of the mid-brain. The mean age of onset of Parkinson’s disease is 55 to 60 years. According to the Parkinson’s Disease Foundation (PDF), approximately 10 million people are estimated to currently live with Parkinson’s disease globally. There are multiple treatment options available in the market to treat patients living with Parkinson’s disease. These include chemotherapy, stem cell therapy, physical therapy and surgical treatment. Among drug therapies, the most potent medication is levodopa/Carbidopa therapy.